Drug Manufacturing and Formulation Program (DMFP)

The Drug Manufacturing and Formulation Program (DMFP) is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract administered by the National Institute of Neurological Disorders and Stroke (NINDS), supporting comprehensive pharmaceutical research and development services. The contract focuses on preclinical and clinical drug development, encompassing a wide range of pharmaceutical manufacturing activities including process development, formulation studies, active pharmaceutical ingredient (API) preparation, analytical method development, stability testing, drug product manufacturing, packaging, quality control, and regulatory documentation. The vehicle enables pharmaceutical research organizations to deliver sophisticated drug development services across therapeutic areas including neurology, infectious diseases, and substance abuse.

Task orders under this IDIQ are consistently awarded to specialized contract development and manufacturing organizations (CDMOs) such as Curia Global Inc. (Amri) and Mriglobal (Midwest Research Institute), with contract values typically ranging from $200,000 to $5,000,000 and performance periods spanning 2-5 years. The task orders are predominantly cost-plus fixed fee or cost-plus award fee, with no set-aside designations, and are primarily funded by civilian agencies within the Department of Health and Human Services, particularly the National Institutes of Health. Key performance locations include research facilities in Missouri, New York, and California, with prime contractors providing services such as medicinal chemistry, chemical development, analytical testing, formulation development, and good manufacturing practices (GMP) production. The contract vehicle supports research across diverse therapeutic domains, facilitating early-stage drug discovery through clinical trial preparation and manufacturing.